Eiger doses first patient in phase 2 LIMT HDV study
Eiger BioPharmaceuticals has dosed the first patient in the Phase 2 LIMT HDV (Lambda Interferon MonoTherapy in HDV) study, a monotherapy trial of pegylated interferon lambda 1a (Lambda) as a potential treatment for chronic hepatitis D virus (HDV) infection.
